Akebia Therapeutics announced that the Swiss Agency for Therapeutic Products has granted marketing authorization for Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKBA:
